Aurobindo Pharma Ltd Share Price

Aurobindo Pharma Limited (APL), founded in 1986, is a pharmaceutical firm that develops, manufactures, and sells active pharmaceutical ingredients (API) and formulations. Currently, the pharma company has 25 modern manufacturing and packaging facilities. It has 9 R&D centres, where more than 1,500 scientists are involved in research and development.

Company History of Aurobindo Pharma

The firm began operations in 1988-1989 with a single production plant in Pondicherry that manufactured Semi Synthetic Penicillins (SSPs). Between 1992 and 1993, they established another manufacturing plant in Hyderabad to produce CMIC Chloride, a bulk medication intermediate. In 1994, the firm combined with Chaitanya Organics Pvt. Ltd. to begin commercial manufacturing of the pharmaceutical formulation unit. In 1995, Aurobindo Pharma Limited went public. Since then, the firm has extended its product line and began manufacturing a variety of formulas. This positively impacted the company, reflected in Aurobindo Pharma's share price NSE and BSE. You can track the Aurobindo share price live on BlinkX.

Milestone of Aurobindo Pharma

From 2003 to 2004, the firm established a subsidiary in China and began commercial manufacturing.
Between 2005 and 2006, Aurobindo Pharma Limited purchased Milpharm Limited, a UK-based company that markets generic formulations in the UK market.
The firm also has a global presence in Brazil, the United States, Puerto Rico, and Portugal.

Production Facilities of Aurobindo Pharma

Aurobindo Pharma Limited has 25 cutting-edge production and packaging facilities, 9 R&D centres, and over 1,500 scientists and analysts participating in R&D operations. Thus, the company's performance has improved, and Aurobindo Pharma Ltd share price has increased. You can check out Aurobindo Pharma's share price today on BlinkX.

Aurobindo Pharma of Business Segments

Aurobindo Pharma Limited's business segments include API development and manufacturing. The US FDA, ANVISA, TGA Australia, the UK MHRA, and other reputable regulatory organisations audit and approve their five production units.

Antiretroviral (ARV): The firm provides many high-quality (US FDA-approved) antiretroviral medications for PLHIV and CLHIV.
AuroZymes is APL's biocatalyst division: It develops and produces biocatalysts used in the chemical and pharmaceutical industries.
APL's Formulations section: It focuses on cost-effective medication research and large-scale manufacture.
Peptides: The company creates peptide-based generic APIs focusing on diabetology and cancer in this business.
R&D: The company's R&D section develops innovative medication delivery technologies and dosage formulations.

Subsidiaries of Aurobindo Pharma

Aurobindo Pharma Limited's subsidiaries include the following:

Helix Healthcare B.V: This subsidiary of Aurobindo Pharma works in the healthcare industry.
Aurovitas Pharma Polska: The company's wholly-owned subsidiary specialising in generic, prescription, and over-the-counter pharmaceuticals throughout 22 therapeutic categories.
Milpharm Limited: It is also a completely owned subsidiary of the firm that manufactures pharmaceutical goods.

Key Personnel of Aurobindo Pharma

K Ragunathan is the non-executive chairman and independent director of Aurobindo Pharma.
The vice chairman and managing director of the company is K Nithyananda Reddy.
M Madan Mohan Reddy and M Sivakumaran are the whole time directors of the firm.

Corporate Actions of Aurobindo Pharma:

The company issued a bonus share of a 1:1 ratio on July 21, 2015.

Aurobindo Pharma Ltd

AUROPHARMA Share Price